Platelet Inhibition to Target Reperfusion Injury
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 228 participants.
Also called NCT03102723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 228 participants
- Sponsor
- Registry
-
NCT03102723
-
- Other papers using this trial's data
- Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Singapore
- Registry status
- Unknown status
Technical summary
Registry record NCT03102723. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-01 (actual); primary completion 2022-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Platelet Inhibition to Target Reperfusion Injury
- Acronym
- PITRI
- Condition
- STEMI
- Intervention (Drug)
- Cangrelor
- Lead sponsor
- National Heart Centre Singapore
- Collaborator
- Tan Tock Seng Hospital
- Collaborator
- National University Hospital, Singapore
- Collaborator
- Khoo Teck Puat Hospital
- Collaborator
- Changi General Hospital
- Collaborator
- Sengkang General Hospital
Record details
- Record id
cardio:ct-nct03102723- Content hash
33356794cf2bec3cbf10656bce1b3fe0721f7d9f96d8b553f6de359e69f05c33